▪ Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology– August 27, 2024
▪ Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark– August 15, 2024
▪ Avicanna Reports Q2 2024– August 14, 2024
▪ Avicanna Announces Changes of Auditors– August 02, 2024
▪ Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore – July 11, 2024
▪ Avicanna Announces Results of Annual General Meeting & Provides Corporate Update– July 10, 2024
▪ Avicanna General Meeting– June 19, 2024
▪ Avicanna Announces USPTO Issuance of Patent on SEDDS Technology– June 19, 2024
▪ Avicanna to Present at the Life Science Investor Forum June 20th, 2024– June 18, 2024
▪ Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter– May 14, 2024
▪ Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa – May 13, 2024
▪ Avicanna Announces Closing of Non-brokered Private Placement – April 18, 2024
▪ Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study – April 10, 2024
▪ Avicanna Reports Full Year 2023 Audited Financial Results– April 2, 2024
▪ Avicanna To Hold Full Year 2023 Earnings Conference Call– March 26, 2024
▪ Avicanna Hosts Symposium on Cannabinoid-based Medicine– February 29, 2024
▪ Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company– February 15, 2024
▪ Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™ – February 13, 2024
▪ Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company – February 5, 2024
▪ Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil – January 30, 2024
▪ Avicanna Announces Closing of Non-Brokered Private Placement – December 4, 2023
▪ Avicanna Reports Q3 2023 Results – November 14, 2023
▪ Avicanna Announces Appointment of Paul Fornazzari to Board of Directors – November 13, 2023
▪ Avicanna To Hold Third Quarter 2023 Earnings Conference Call – November 1, 2023
▪ Avicanna Provides Update on the Successful Launch of MyMedi.ca – October 11, 2023
▪ Retirement of Chandra Panchal, PhD from the Board of Directors – September 01, 2023
▪ Avicanna Reports Q2 2023 Financial Statement – August 15, 2023
▪ Avicanna Announces Closing of Acquisition and Launch of MyMedi.ca – August 1, 2023
▪ Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform – June 28 2023
▪ Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay – July 17 2023
▪ Avicanna Provides Corporate Update and Preliminary Q2 Results – June 28 2023
▪ Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International markets – June 26 2023
▪ Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”) – June 22 2023
▪ Avicanna and Langara College Announce Cannabinoid-Based Translational Research Collaboration and NSERC Grant – June 13, 2023
▪ Shoppers Drug Mart and Avicanna Execute Definitive Asset Purchase Agreement for Avicanna’s Acquisition of the Medical Cannabis by Shoppers Business – May 29, 2023
▪ Avicanna Announces Results of Annual General and Special Meeting and Provides Corporate Update – May 17, 2023
▪ Avicanna Reports Q1 2023 Financial Statement – May 16, 2023
▪ Avicanna and Northern Green Canada Execute Master Service Agreement to Operationalize MyMedi.ca – May 4, 2023
▪ Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2022 – April 3, 2023
▪ Shoppers Drug Mart partners with Avicanna to transition Medical Cannabis by Shoppers – March 28, 2023
▪ Avicanna Announces Closing of Non-Brokered Private Placement – March 21, 2023
▪ Avicanna Announces Warrant and Debenture Repricing and Amendments – January 30, 2023
▪ Avicanna Subsidiary Santa Marta Golden Hemp S.A.S. Completes First Commercial Export of feminized Cannabis Seeds from Colombia to Spain – January 17, 2023
▪ Avicanna Announces Organizational Change in Avicanna LATAM S.A.S – December 30, 2022
▪ Avicanna Announces Promotion of Phillip Cardella to Chief Financial Officer and Closing of Non-Brokered Private Placement – December 21 2022
▪ Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the RHO PhytoTM CBG Transdermal Gel Topical Product– December 14 2022
▪ Avicanna Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market – November 29, 2022
▪ Avicanna Reports Q3 2022 Financial Statement– November 14, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement – November 11, 2022
▪ Avicanna Announces Extension of Term Loan – October 31, 2022
▪ Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy – October 20, 2022
▪ Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals – October 18, 2022
▪ Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto – September 15, 2022
▪ Avicanna Expands its Epilepsy Research Program with a New Collaboration with the University of Toronto – September 15, 2022
▪ Avicanna Announces Results of Annual General and Special Meeting – September 01, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – August 17, 2022
▪ Avicanna Reports Q2 2022 Financial Statement – August 15, 2022
▪ Avicanna and Ei. Ventures Enter into an Agreement to Develop and Commercialize Adaptogen Nutraceuticals – July 20, 2022
▪ Avicanna Announces Date of Upcoming Annual General and Special Meeting of Shareholders   – July 11, 2022
▪ Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
▪ Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa – June 24, 2022
▪ Avicanna Completes its First Commercial Export of its Derma-Cosmetics Brand Pura H&W™ into the European Union – July 07, 2022
▪ Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa – June 24, 2022
▪ Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho – June 09, 2022
▪ Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho – May 24, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – May 12, 2022
▪ Avicanna Announces Closing of Strategic Private Placement – May 6, 2022
▪ Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market  – April 28, 2022
▪ Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company – April 28, 2022
▪ Avicanna Enters into Exclusive License and Supply Agreement with Major South American Pharmaceutical Company  – April 13, 2022
▪ Avicanna Expands its Derma-Cosmetics Brand Pura H&W™ into the European Union through a Partnership with Bio-Gate AG – April 5, 2022
▪ Avicanna Announces Filing of Annual Financial Statements for Year Ended December 31, 2021 – March 31, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement – March 31, 2022
▪ Avicanna Enters into a Strategic Partnership with Tetra Bio-Pharma – February 10, 2022
▪ Avicanna Provides Q4-2021 Results and Corporate Highlights as well as Fiscal 2022 Guidance – February 02, 2022
▪ Avicanna Announces Closing of Non-Brokered Private Placement of Convertible Debenture Units– January 28, 2022
▪ Avicanna Enters Master Supply Agreement with Chilean Pharmaceutical Pioneer Knop Laboratorios S.A.– January 14, 2022
▪ Avicanna Announces the Appointment of Stephen Kim as Chief Legal Officer & General Counsel– January 10, 2022
▪ Avicanna Announces Changes to its Board of Directors– Jan. 4, 2022
▪ Avicanna Completes First Commercial Export of CBG from Colombia to Czech Republic– Dec. 24, 2021
▪ Avicanna Launches its Clinically Backed CBD Derma-cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom– Dec. 22, 2021
▪ Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference– Dec. 10, 2021
▪ Avicanna Files a Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases– Dec. 06, 2021
▪ Avicanna Enters into an Intellectual Property Licensing and Distribution Agreement with Established Pharmaceutical Company in Argentina– Nov. 30, 2021
▪ Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados– Nov. 25, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for the Three-Month Period Ending September 30, 2021, Demonstrating Progressive Commercialization Results– Nov. 12, 2021
▪ Avicanna Announces Resignation of Director– Nov. 11, 2021
▪ Avicanna Inc. to Host Third Quarter 2021 Investor Conference Call on November 12 and Announces Warrant Repricing– Nov. 8, 2021
▪ Avicanna Announces Management Change– Nov. 5, 2021
▪ Avicanna´s subsidiary obtains Good Agricultural and Collection Practices (“GACP”) Certification in Colombia– Nov. 4, 2021
▪ Avicanna Completes Commercial Export of CBD Isolate and CBD Full Spectrum Psychoactive Derivatives from Colombia to Chile– Oct. 22, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $3.9 Million and Announces Warrant Repricing– Oct. 19, 2021
▪ Avicanna Completes First Commercial Export of Feminized Cannabis Seeds from Colombia to Peru and Argentina– October 1, 2021
▪ Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy– Sept. 24, 2021
▪ Avicanna Completes Registration and Commercial Export of its Evidence-Based CBD Dermacosmetics Brand, Pura Earth, in Ecuador– Sept. 16, 2021
▪ Avicanna Announces Filing of Interim Financial Statements for Period Ended June 30, 2021 and Provides Corporate Update– Sept. 10, 2021
▪ Avicanna Announces Filing of Annual Financial Statements For Year Ended December 31, 2020– Sept. 03, 2021
▪ Avicanna Completes First Commercial Export of Aureus Branded Full Spectrum Psychoactive CBD Cannabis Extracts to Brazil– Aug 27, 2021
▪ Avicanna Expands Sales of Pura Earth and RHO Phyto Branded Topicals into Alberta’s Retail Channels– Aug 24, 2021
▪ Avicanna Enters Partnership with Heritage Cannabis Holdings Corp. to Commercialize Evidence-Based Topical Products through Heritage’s Medical Cannabis Channels– Aug 11, 2021
▪ Avicanna Announces Partial Revocation of Cease Trade Order and Proposed Financing– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru– August 3, 2021
▪ Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis– July 28, 2021
▪ Avicanna Announces Change of Auditor– July 19, 2021
▪ Avicanna and Bio-Gate Complete First Phase of Development on Cannabidiol (CBD) and MicroSilver BG™ Based Skin Care Products for Global Commercialization– June 29, 2021
▪ Avicanna Announces Results of Annual General Meeting and Provides Corporate Update– June 24, 2021
▪ Avicanna Expands The Canadian RHO Phyto Product Offerings With The Addition Of THC-Free High CBD Oral And Sublingual Formulation Across Medical And Adult Use Channels– June 15, 2021
▪ Avicanna Announces Mailing of Management Information Circular and Proposed Board Changes– June 3, 2021
▪ Avicanna’s Evidence-Based and Dermatologist Tested CBD Derma-Cosmetic Brand Pura Earth™ to be Launched in Adult-Use and Medical Channels Across Canada in Q2 2021.– May 26, 2021
▪ Avicanna Makes RHO Phyto™ Medical Cannabis Products Available In Canadian Hospital Pharmacies Through Agreement with Sunnybrook Hospital – May 6, 2021
▪ Avicanna Provides Bi-Weekly Update On Status Of Management Cease Trade Order – April 26, 2021
▪ Avicanna Announces Receipt of Management Cease Trade Order and Provides Bi-Weekly Status Update – April 12, 2021
▪ Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order – March 29, 2021
▪ Avicanna Closes Non-Brokered Private Placement Raising $5.6 Million – Mar 4, 2021
▪ Avicanna Announces Exercise And Closing Of Over-Allotment Option – Dec 31, 2020
▪ Avicanna Announces Closing of Public Offering of Units – Dec 8, 2020
▪ Avicanna Announces Overnight Marketed Public Offering of Units – Nov 12, 2020
▪ Avicanna Reports Third Quarter 2020 Financial Results and Provides Corporate Update – Nov 12, 2020
▪ Avicanna Closes Non-Brokered Private Placement Raising $2.7 Million – Aug 18, 2020
▪ Avicanna Reports Second Quarter 2020 Financial Results and Provides Corporate Update – Aug 17, 2020
▪ Avicanna Reports First Quarter 2020 Financial Results and Provides Corporate Update – May 25, 2020
▪ Avicanna Closes Non-Brokered Private – Placement with Group of Strategic Investors and Announces Warrant Re-Pricing – April 21, 2020
▪ Avicanna Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update – April 15, 2020
▪ Avicanna Closes First Tranche of Private Placement – January 24, 2020
▪ Avicanna Reports Third Quarter 2019 Financial Results – Nov. 14, 2019
▪ Avicanna Completes its First Exportation of Cannabinoids from Colombia to Canada for Scientific Purposes – Aug 23, 2019
▪ Avicanna Reports Second Quarter 2019 Financial Results – Aug 14, 2019
▪ Avicanna Commences Trading on the TSX Under the Symbol “AVCN” – July 18, 2019
▪ Avicanna Announces TSX Listing Date – July 16, 2019
▪ Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX – July 10, 2019
▪ Avicanna Closes Oversubscribed $22.1 Million Special Warrant Offering – April 18, 2019
▪ Avicanna Announces Filing of Preliminary Prospectus – January 21, 2019
▪ Avicanna Inc. Acquires 60% Stake in Colombian Medical Marijuana Firm Santa Marta Golden Hemp – August 16, 2018
▪ Avicanna Completes 2nd Equity Financing & Welcomes New Strategic Shareholder – January 29, 2018
▪ Avicanna Closes its First Equity Financing and Announces its Residency at Johnson & Johnson Innovation, JLABS @ Toronto – May 26, 2017